HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 501–600 of 1,008
Zhao, Y., Bi, K. S., Gao, Z., Chen, T., Liu, H., Xiè, J., Chéng, J., Fù, Y., & Jiāng, D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00673 · Cited by 76
Functional principles and regulation of molecular chaperones
Dahiya, V., & Buchner, J. (2019) · Advances in Protein Chemistry and Structural Biology · doi:10.1016/bs.apcsb.2018.10.001 · Cited by 76
Xu, Y.-M., Marron, M. T., Seddon, E., McLaughlin, S. P., Ray, D. T., Whitesell, L., & Leslie Gunatilaka, A. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.091 · Cited by 75
Self-citationProtein Quality Control Degradation in the Nucleus
Enam, C., Geffen, Y., Ravid, T., & Gardner, R. G. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012730 · Cited by 84
An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
Shirai, Y., Chow, C. C. T., Kambe, G., Suwa, T., Kobayashi, M., Takahashi, I., Harada, H., & Nam, J. (2021) · Cancers · doi:10.3390/cancers13112813 · Cited by 79
Kang, B.-H. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.1.1 · Cited by 74
“from misfolding and aggregation, consequently regulating the cellular function of clients (3).”
BackgroundInfluentialRegulation of Embryonic Stem Cell Pluripotency by Heat Shock Protein 90
Bradley, E., Bieberich, E., Mivechi, N. F., Tangpisuthipongsa, D., & Wang, G. (2012) · Stem Cells · doi:10.1002/stem.1143 · Cited by 79
Acquaviva, J., He, S., Zhang, C., Jimenez, J.-P., Nagai, M., Sang, J., Sequeira, M., Smith, D. L., Ogawa, L. S., Inoue, T., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0004 · Cited by 75
“The molecular chaperone HSP90 plays an essential role in regulating the maturation and functional stability of an extensive array of cellular client proteins, an activity that is often exploited by cancer cells to confer aberrant proliferative, survival, and/or metastatic potential (12, 13).”
BackgroundInhibitors of HSP90 in melanoma
Mielczarek-Lewandowska, A., Hartman, M. L., & Czyż, M. (2019) · APOPTOSIS · doi:10.1007/s10495-019-01577-1 · Cited by 78
Lamoth, F., Juvvadi, P. R., Soderblom, E. J., Moseley, M. A., Asfaw, Y. G., & Steinbach, W. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02286-13 · Cited by 74
“Hsp90 is an essential molecular chaperone that activates multiple client proteins (9).”
BackgroundCellular and Molecular Adaptation of Arabian Camel to Heat Stress
Hoter, A., Rizk, S. E., & Naim, H. Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00588 · Cited by 76
“Additionally, HSP90 candidates are linked to many pathologies such as cancer, inflammation and neurodegenerative diseases (Whitesell and Lindquist, 2005; Luo et al., 2010; Sevin et al., 2015).”
BackgroundPurine-Scaffold Hsp90 Inhibitors
Taldone, T., & Chiosis, G. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895737 · Cited by 82
“Heat shock protein 90 (Hsp90) is a molecular chaperone protein that is widely expressed and activated in cancers [1-3].”
BackgroundInfluentialFlom, G., Behal, R. H., Rosen, L., Cole, D. G., & Johnson, J. L. (2007) · Biochemical Journal · doi:10.1042/bj20070084 · Cited by 73
Breinig, M., Caldas-Lopes, E., Goeppert, B. F., Malz, M., Rieker, R. J., Bergmann, F., Schirmacher, P., Mayer, M. P., Chiosis, G., & Kern, M. A. (2009) · Hepatology · doi:10.1002/hep.22912 · Cited by 76
“Reagents PU-H71 (8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9(3-isopropylamino)propyl)-9H-purin-6-amine) was synthesized as previously reported.”
BackgroundMethodTong, K., Lok, C., Wan, P., Hu, D., Fung, Y. M. E., Chang, X., Huang, S., Jiang, H., & Che, C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1915202117 · Cited by 196
“contains functional cysteine residues (48, 49).”
Huck, J. D., Que, N. L., Hong, F., Li, Z., & Gewirth, D. T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.079 · Cited by 73
“Hsp90s govern the maintenance and activation of many essential proteins (Marzec et al., 2012; Whitesell and Lindquist, 2005).”
BackgroundLiu, W., Li, J., Zhang, P., Hou, Q., Feng, S., Liu, L., Cui, D., Shi, H., Fu, Y., & Luo, Y. (2019) · Cancer Science · doi:10.1111/cas.14143 · Cited by 78
Defining the Requirements for Hsp40 and Hsp70 in the Hsp90 Chaperone Pathway
Cintron, N. S., & Toft, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605417200 · Cited by 70
Hsp90—From signal transduction to cell transformation
Brown, M. A., Zhu, L., Schmidt, C., & Tucker, P. W. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.054 · Cited by 89
“These ‘client proteins’ include protein kinases, nuclear hormone receptors, transcription factors, and an array of other essential proteins [8].”
BackgroundMustafi, S. B., Chakraborty, P. K., & Raha, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008719 · Cited by 73
Jhaveri, K. L., Miller, K. D., Rosen, L. S., Schneider, B. P., Chap, L. I., Hannah, A. L., Zhong, Z., Ma, W., Hudis, C. A., & Modi, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3200 · Cited by 73
“When Hsp90 is inhibited, its client proteins are rendered unstable and ultimately undergo ubiquitination followed by degradation via the proteasomal pathway (1-3).”
BackgroundNK Cell Protease Granzyme M Targets α-Tubulin and Disorganizes the Microtubule Network
Bovenschen, N., de Koning, P. J. A., Quadir, R., Broekhuizen, R., Damen, M. J. A., Froelich, C. J., Slijper, M., & Kummer, J. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.8184 · Cited by 73
“HSP90 plays an essential role in maintaining stability and activity of its client proteins, including a set of signaling proteins that regulate key pathways in cell survival and oncogenesis (28).”
BackgroundUnconventional Secretion of Heat Shock Proteins in Cancer
Santos, T. G., Martins, V. R., & Hajj, G. N. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050946 · Cited by 75
“Secretion of HSP90AA1 was implicated in increased cell mobility and cancer invasiveness [3].”
BackgroundAdvances in the structures, mechanisms and targeting of molecular chaperones
Gu, J., He, Y., He, C., Zhang, Q., Huang, Q., Bai, S., Wang, R., You, Q., & Wang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02166-2 · Cited by 85
“311,312 Protein kinases, including AKT, cyclin-CDK4 and RAF1 kinases, are the most common client proteins of the HSP90 chaperone system (Fig.”
Fionda, C., Soriani, A., Zingoni, A., Santoni, A., & Cippitelli, M. (2015) · BioMed Research International · doi:10.1155/2015/178698 · Cited by 72
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
He, S., Smith, D. L., Sequeira, M., Sang, J., Bates, R. C., & Proia, D. A. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0095-4 · Cited by 71
“Beyond an essential role in maintaining normal tissue homeostasis, the chaperoning activity of HSP90 is now recognized as critical for the function of many of these same clients, as well as mutated and aberrantly expressed forms, which contribute to nearly every aspect of the tumorigenic process including immortality,…”
BackgroundErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Friedländer, E., Barok, M., Szöllõsi, J., & Vereb, G. (2008) · Immunology Letters · doi:10.1016/j.imlet.2007.12.001 · Cited by 79
“Hsp90 exerts ts chaperone function to maintain the conformation, activity, urnover and localization of many proteins that are involved in roliferation and survival [189], including ErbB2, ERK1/2 and t d S Letters 116 (2008) 126–140”
BackgroundStellas, D., Karameris, A., & Patsavoudi, E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1585 · Cited by 65
Heat shock proteins in multiple myeloma
Zhang, L., Fok, J. H. L., & Davies, F. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1584 · Cited by 79
“When Hsp90 exchanges ADP to ATP, its open to shut conformational change leads to the dissociation of Hsp70/40 and HOP and the association of another set of co-chaperones such as CDC37 and p23 to form the mature complex [37, 38].”
BackgroundDrug-induced apoptosis in yeast
Almeida, B., Silva, A., Mesquita, A., Sampaio‐Marques, B., Rodrigues, F. J. S., & Ludovico, P. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.005 · Cited by 76
“The molecular chaperone HSP90, required to ensure the correct conformation, activity, intracellular localization, and proteolytic turnover of a range of proteins that are involved in cell growth, differentiation, and survival [151,152], is also an attractive target for tumour therapy.”
BackgroundSabath, E., Negoro, H., Beaudry, S., Paniagua, M., Angelow, S., Shah, J. V., Grammatikakis, N., Yu, A. S. L., & Denker, B. M. (2008) · Journal of Cell Science · doi:10.1242/jcs.014878 · Cited by 82
“The Hsp90 chaperone complex includes numerous co-chaperones (reviewed in Whitesell and Lindquist, 2005) and a novel N-terminal myristoylated Hsp90 isoform (Hsp90N) is expressed in epithelial cells (Grammatikakis Jo ur na l o f C el l S ci en ce 819G 12 regulation of tight junctions et al., 2002).”
BackgroundMartins, A. S., Ordóñez, J. L., Sánchez, A. G., Herrero, D., Sevillano, V., Osuna, D., Mackintosh, C., Caballero, G., Otero, A. P., Poremba, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3074 · Cited by 78
Li, Y., Karagöz, G. E., Seo, Y. H., Zhang, T., Jiang, Y., Yu, Y., Duarte, A. M. S., Schwartz, S. J., Boelens, R., Carroll, K. S., et al. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.11.004 · Cited by 71
“Inhibition of Hsp90 may result in simultaneous degradation of multiple client proteins, such as kinases, hormone receptors and transcription factors, in cancers [12,13].”
BackgroundJohnson, J. L., Halas, A., & Flom, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01034-06 · Cited by 72
“The Hsc82-Sba1-Cpr6 complex, which interacts with client proteins late in the folding pathway (14, 28, 39), was proposed to be the complex capable of hydrolysis (32).”
BackgroundMbonye, U. R., Wang, B., Gokulrangan, G., Shi, W., Yang, S., & Karn, J. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001347 · Cited by 81
Wainberg, Z. A., Anghel, A., Rogers, A. M., Desai, A. J., Kalous, O., Conklin, D. F., Ayala, R., O’Brien, N. A., Quadt, C., Akimov, M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0507 · Cited by 70
“HSP90 accounts for 1% to 2%of all proteins and it consists of 3 domains; a 24 to 28 kDaNH2-terminal region, a 33 to 44 kDAmiddle region, and an 11 to 15 kDa COOH domain, all of which are involved in ATP binding (7).”
BackgroundKoga, T., Kobayashi, Y., Tomizawa, K., Suda, K., Kosaka, T., Sesumi, Y., Fujino, T., Nishino, M., Ohara, S., Chiba, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.019 · Cited by 71
Floer, M., Bryant, G. O., & Ptashne, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800053105 · Cited by 79
Samarasinghe, B., Wales, C. T. K., Taylor, F. R., & Jacobs, A. T. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.014 · Cited by 71
“However, in tumor cells it supports the expression of oncogenes, inhibits cell death processes and drives tumorigenesis [1, 2].”
BackgroundMoonlighting proteins in cancer
Min, K., Lee, S., & Baek, S. J. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.022 · Cited by 75
Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
Li, F., Peiris, M. N., & Donoghue, D. J. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.12.005 · Cited by 70
Tomiyama, E., Matsuzaki, K., Fujita, K., Shiromizu, T., Narumi, R., Jingushi, K., Koh, Y., Matsushita, M., Nakano, K., Hayashi, Y., et al. (2021) · Cancer Science · doi:10.1111/cas.14881 · Cited by 74
Tatokoro, M., Koga, F., Yoshida, S., Kawakami, S., Fujii, Y., Neckers, L., & Kihara, K. (2011) · International Journal of Cancer · doi:10.1002/ijc.26475 · Cited by 69
“After treatment with Hsp90 inhibitors, another mechanism conferring treatment resistance may emerge: once heat shock factor (HSF)-1 is released from an Hsp90-containing heterocomplex by abrogation of Hsp90 function,(45) HSF-1 translocates to the nucleus, binds to heat shock elements and transactivates Hsp90, 70 and 27…”
BackgroundStress Inducibility of SIRT1 and Its Role in Cytoprotection and Cancer
Raynes, R., Brunquell, J., & Westerheide, S. D. (2013) · Genes & Cancer · doi:10.1177/1947601913484497 · Cited by 72
Proia, D., Zhang, C.-H., Sequeira, M., Jimenez, J., He, S.-Q., Spector, N., Shapiro, G., Tolaney, S., Nagai, M., Acquaviva, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2166 · Cited by 65
“This result is consistent with the premise that HSP90 inhibitors may best be exploited in the clinical setting as chemotherapeutic sensitizers to provide effective antitumor activity, block repair/resistance mechanisms, and reduce treatment-related toxicities (14).”
ResultAllosteric Modulation of Human Hsp90α Conformational Dynamics
Penkler, D. L., Atılgan, C., & Bishop, Ö. T. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00630 · Cited by 70
Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone
Hurst, D. R., Mehta, A., Moore, B. P., Phadke, P. A., Meehan, W. J., Accavitti, M. A., Shevde, L. A., Hopper, J. E., Xie, Y., Welch, D. R., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.08.005 · Cited by 74
“The Hsp90 chaperone complex is activated during cell stress (such as cancer metastasis) to associate with distinct client proteins [30].”
BackgroundFrick, K. M. (2012) · Behavioral Neuroscience · doi:10.1037/a0026660 · Cited by 77
“Hsp70 is an integral part of the cytosolic estrogen receptor protein complex that keeps nuclear ERs inactive until they bind estrogens and translocate to the nucleus (Whitesell & Lindquist, 2005).”
ATPases as Drug Targets: Insights from Heat Shock Proteins 70 and 90
Massey, A. J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100342z · Cited by 77
Xia, Y., Liu, Y., Rocchi, P., Wang, M., Fan, Y., Qu, F., Iovanna, J., & Peng, L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.09.043 · Cited by 68
“Among the superfamily of HSPs, HSP90, HSP70 and HSP27 chaperones are particularly attractive as anticancer targets due to their function as master regulators of multiple oncoproteins and their tumorigenic properties [7–14].”
BackgroundAmbati, S. R., Lopes, E. C., Kosugi, K., Mony, U., Zehir, A., Shah, S. K., Taldone, T., Moreira, A. L., Meyers, P. A., Chiosis, G., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.005 · Cited by 68
“HSP90 in particular, is a critical component of the multi-chaperone complexes that regulate the disposition and activity of a large number of cellular kinases, transcription factors, and other molecules (Whitesell and Lindquist, 2005).”
BackgroundCell Biology of Membrane Trafficking in Human Disease
Howell, G. J., Holloway, Z. G., Cobbold, C., Monaco, A. P., & Ponnambalam, S. (2006) · International review of cytology · doi:10.1016/s0074-7696(06)52005-4 · Cited by 78
“Many Hsp90 client proteins are implicated in cell cycle progression, proliferation, and angiogenesis (Whitesell and Lindquist, 2005).”
Apo‐Hsp90 coexists in two open conformational states in solution
Bron, P., Giudice, E., Rolland, J., Buey, R. M., Barbier, P., Díaz, J. F., Peyrot, V., Thomas, D., & Garnier, C. (2008) · Biology of the Cell · doi:10.1042/bc20070149 · Cited by 76
Insights into designing the dual-targeted HER2/HSP90 inhibitors
Chen, C., & Chen, C. Y. (2010) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2010.04.002 · Cited by 67
Advancing Cell Biology Through Proteomics in Space and Time (PROSPECTS)
Lamond, A. I., Uhlén, M., Horning, S. R., Makarov, A., Robinson, C. V., Serrano, L., Hartl, F. U., Baumeister, W. P., Werenskiold, A. K., Andersen, J., et al. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.017731 · Cited by 76
“Inhibition of heat shock proteins has been shown to be a clinically promising avenue in cancer treatment (43).”
BackgroundThe role of heat shock proteins in the regulation of fibrotic diseases
Zhang, X., Zhang, X., Huang, W., & Ge, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111067 · Cited by 67
Kang, B. H., Tavecchio, M., Goel, H. L., Hsieh, C.-C., Garlick, D. S., Raskett, C. M., Lian, J. B., Stein, G. S., Languino, L. R., & Altieri, D. C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.9 · Cited by 71
“In this context, the molecular chaperone heat shock protein-90 (Hsp90) is a nodal cancer gene (Whitesell and Lindquist, 2005), controlling the folding and/or maturation of client proteins involved in tumour cell proliferation, survival and adaptation (Trepel et al, 2010).”
BackgroundChen, W., Sin, S., Wen, K. W., Damania, B., & Dittmer, D. P. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003048 · Cited by 69
“Overexpression of Hsp90 has been detected in a variety of cancers [3,4,5].”
BackgroundMoses, M. A., Henry, E. C., Ricke, W. A., & Gasiewicz, T. A. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0224 · Cited by 64
“HSPs are upregulated in response to stressors including hypoxia, low nutrient availability, mutations, and overexpression of proteins/oncogenes (11, 12), characteristics important in cancer progression.”
Tan, S. S. Y., Ahmad, I., Bennett, H. L., Singh, L. B., Nixon, C., Seywright, M. M., Barnetson, R. J., Edwards, J., & Leung, H. Y. (2010) · The Journal of Pathology · doi:10.1002/path.2795 · Cited by 73
“The Hsp70–HOP–hsp90 supercomplex requires the initiation by its co-chaperones Hsp70 and HOP to modulate and maintain its client proteins, including steroid hormone receptors in a latent but primed state [10].”
BackgroundSattin, S., Tao, J., Vettoretti, G., Moroni, E., Pennati, M., Lopergolo, A., Morelli, L., Bugatti, A., Zuehlke, A. D., Moses, M., et al. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201502211 · Cited by 69
Shimp, S. K., Chafin, C. B., Regna, N. L., Hammond, S. E., Read, M. A., Caudell, D. L., Rylander, M. N., & Reilly, C. M. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.5 · Cited by 82
Stravopodis (2009) · International Journal of Oncology · doi:10.3892/ijo_00000353 · Cited by 79
“Cisplatin seems to induce a conformational change in the Hsp90 amino-terminal domain (Hsp90N), while it can also block the aggregation prevention activity of the Hsp90 carboxyl-terminal domain (Hsp90C) (28,29,77).”
BackgroundSchmidt, A., von Woedtke, T., & Bekeschus, S. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9816072 · Cited by 69
Patel, H., Patel, P. D., Ochiana, S. O., Yan, P., Sun, W., Patel, M. R., Shah, S. K., Tramentozzi, E., Brooks, J. C., Bolaender, A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00197 · Cited by 67
“2-((6-Iodobenzo[d][1,3]dioxol-5-yl)thio)-1H-imidazo[4,5-c]-pyridin-4-amine (21f): Yield: 78%.”
Wang, B., Liu, Y., Huang, L., Chen, J., Li, J. J., Wang, R., Kim, E., Chen, Y., Justicia, C., Sakata, K., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.104 · Cited by 67
Mitochondrial-targeted penetrating peptide delivery for cancer therapy
Wu, J., Li, J., Wang, H., & Liu, C.-B. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1517750 · Cited by 67
“In tumor cells, Hsp90 is thought to orchestrate a broad cell-survival program [91], which has been linked to stabilization of cell viability effectors [92], adaptation to unfavorable environments [93], and inhibition of mitochondria-initiated apoptosis [94].”
BackgroundLigand and Protein Fishing with Heat Shock Protein 90 Coated Magnetic Beads
Marszałł, M. P., Moaddel, R., Kole, S., Gandhari, M., Bernier, M., & Wainer, I. W. (2008) · Analytical Chemistry · doi:10.1021/ac801153h · Cited by 67
Hsp110 Chaperones Control Client Fate Determination in the Hsp70–Hsp90 Chaperone System
Mandal, A. K., Gibney, P. A., Nillegoda, N. B., Theodoraki, M. A., Caplan, A. J., & Morano, K. A. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-09-0779 · Cited by 66
“Interruption of the Hsp70– Hsp90-folding cycle through genetic or pharmacological means, such as the specific inhibitor geldanamycin (GA), can result in ubiquitinylation and degradation of the client protein (Whitesell and Lindquist, 2005).”
BackgroundYoussef, M. E., Cavalu, S. D., Hasan, A. M., Yahya, G., Abdel-Dayem, M. A., & Saber, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055014 · Cited by 73
Lakhssassi, N., Doblas, V. G., Rosado, A., del Valle, A. E., Posé, D., Jimenez, A. J., Castillo, A. G., Valpuesta, V., Borsani, O., & Botella, M. A. (2012) · PLANT PHYSIOLOGY · doi:10.1104/pp.111.188920 · Cited by 66
“Of all proteins containing TPR domains, Hsp90 is arguably the best studied (Sangster and Queitsch, 2005; Whitesell and Lindquist, 2005; Pratt et al., 2008; Taipale et al., 2010).”
BackgroundHunter, M. C., O’Hagan, K. L., Kenyon, A., Dhanani, K. C. H., Prinsloo, E., & Edkins, A. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086842 · Cited by 66
“It is thought that Hsp90N is primarily membrane associated due to its unique hydrophobic N-terminal domain [16].”
Backgroundp63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis
Matin, R., Chikh, A., Chong, S. L. P., Mesher, D., Graf, M., Sanzà, P., Senatore, V., Scatolini, M., Moretti, F., Leigh, I. M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121439 · Cited by 66
“This could be a result of hetero oligomer formation or cotranslocation by molecular chaperones recognized to transport p53, e.g., hsp90 or hsp70 (Walerych et al., 2004, 2009; Whitesell and Lindquist, 2005).”
Backgroundvan der Kraan, A. G. J., Chai, R. C., Singh, P. P., Lang, B. J., Xu, J.-K., Gillespie, M., Price, J. T., & Quinn, J. M. (2013) · Biochemical Journal · doi:10.1042/bj20121626 · Cited by 65
Baquero-Pérez, B., & Whitehouse, A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005274 · Cited by 69
“The functional importance of the HSP70 and HSP90 families of molecular chaperones is exemplified by their emerging implications in a variety of diseases, including cancer [4, 5], neurodegeneration [6] or viral infection [7, 8].”
BackgroundCanella, A., Welker, A. M., Yoo, J. Y., Xu, J., Abas, F. S., Kesanakurti, D., Nagarajan, P., Beattie, C. E., Sulman, E. P., Liu, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3151 · Cited by 67
“HSP90 is expressed in the cytoplasm of glioma xenograft cells HSP90 is known to be overexpressed in several solid and hematologic malignancies (10).”
BackgroundProisy, N., Sharp, S. Y., Boxall, K. J., Connelly, S., Roe, S. M., Prodromou, C., Slawin, A. M. Z., Pearl, L. H., Workman, P., & Moody, C. J. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.015 · Cited by 71
Song, D., Guo, M. Z., Xu, S., Xiaotian, S., Bai, B., Li, Z., Chen, J., An, Y., Nie, Y., Wu, K., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01951-5 · Cited by 68
Molecular Cochaperones: Tumor Growth and Cancer Treatment
Calderwood, S. K. (2013) · Scientifica · doi:10.1155/2013/217513 · Cited by 68
“Cancers appear to become addicted to these co-chaperones in a similar way to their dependence on the primary chaperones, requiring these co-factors to maintain elevated levels of oncogenes which are often mutated during carcinogenesis [18, 21].”
BackgroundInfluentialHsp70/Hsp90 Organising Protein (Hop): Beyond Interactions with Chaperones and Prion Proteins
Baindur‐Hudson, S., Edkins, A. L., & Blatch, G. L. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-319-11731-7_3 · Cited by 71
“2009) as well as in tumorigenesis (Kamal et al. 2004; Müller et al. 2004; Whitesell and Lindquist 2005; Chiosis 2006; Neckers 2007; Mahalingam et al. 2009; Trepel et al. 2010; Miyata et al. 2013) .”
BackgroundKnock Down of Heat Shock Protein 27 (HspB1) Induces Degradation of Several Putative Client Proteins
Gibert, B., Eckel, B., Fasquelle, L., Moulin, M., Bouhallier, F., Gonin, V., Mellier, G., Simon, S., Kretz‐Remy, C., Arrigo, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029719 · Cited by 69
“In this regard, one member of the heat shock protein family, Hsp90, is well characterized to interact with an important number of client proteins implicated in cell cycle regulation, signal transduction or gene transcription [18,19].”
BackgroundMirjolet, C., Lanneau, D., Brunet, M., Bouchot, A., Cartier, J., Jacquel, A., Ducoroy, P., Cathelin, S., Décologne, N., Chiosis, G., et al. (2008) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402320 · Cited by 66
Lagarrigue, F., Dupuis-Coronas, S., Ramel, D., Delsol, G., Tronchère, H., Payrastre, B., & Gaits‐Iacovoni, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0861 · Cited by 69
Kumano, M., Furukawa, J., Shiota, M., Zardan, A., Zhang, F., Beraldi, E., Wiedmann, R. M., Fazli, L., Zoubeidi, A., & Gleave, M. E. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0072 · Cited by 68
“In particular, molecular chaperones play an important role in many stress-activated cell signaling and transcriptional regulatory networks [17, 42].”
Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90β
Yim, K. H., Prince, T. L., Qu, S., Bai, F., Jennings, P. A., Onuchic, J. N., Theodorakis, E. A., & Neckers, L. Μ. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606655113 · Cited by 67
“When the chaperone cycle is blocked by Hsp90 inhibitors, client proteins are unable to fully mature, and instead become ubiquitinated and degraded within the proteasome (16, 17).”
BackgroundAdaptive response of resistant cancer cells to chemotherapy
Chern, Y., & Tai, I. T. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0005 · Cited by 76
Heat shock protein 90 targeting therapy: state of the art and future perspective
Tatokoro, M., Koga, F., Yoshida, S., & Kihara, K. (2015) · EXCLI journal · doi:10.17179/excli2014-586 · Cited by 64
“…homeostasis, it is an ATPdependent molecular chaperone that plays a role in stabilizing and activating more than 200 client proteins, many of which are essential for constitutive cell signaling and adaptive responses to stress (Neckers, 2007; Trepel et al., 2010, Whitesell and Lindquist; 2005).”
BackgroundSenolytic targets and new strategies for clearing senescent cells
Ge, M., Hu, L., Ao, H.-S., Zi, M., Kong, Q., & He, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111468 · Cited by 67
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 70
Function of Cytosolic Chaperones in Tom70-Mediated Mitochondrial Import
C.Y. Fan, A., & C. Young, J. (2011) · Protein & Peptide Letters · doi:10.2174/092986611794475020 · Cited by 64
Maynard, J. C., Pham, T. T., Zheng, T., Jockheck-Clark, A. R., Rankin, H. B., Newgard, C. B., Spana, E. P., & Nicchitta, C. V. (2010) · Developmental Biology · doi:10.1016/j.ydbio.2009.12.023 · Cited by 67
“In this capacity, Hsp90 serves critical roles in the maintenance and expression of polymorphic signaling pathway variants that influence morphogenesis and survival (Rutherford et al., 2007; Whitesell and Lindquist, 2005).”
BackgroundHsp90 as a Gatekeeper of Tumor Angiogenesis: Clinical Promise and Potential Pitfalls
Bohonowych, J. E., Gopal, U., & Isaacs, J. S. (2010) · Journal of Oncology · doi:10.1155/2010/412985 · Cited by 63
“Therefore, the salient finding that RTKs comprise the largest category of Hsp90 client proteins [7, 68, 80] (Figure 1) holds clinical promise for the ability of Hsp90-directed agents to suppress angiogenic signaling and overcome therapeutic resistance in diverse cancers.”
BackgroundGallon, E., Matini, T., Sasso, L., Mantovani, G., Armiñán, A., Sanchis, J., Caliceti, P., Alexander, C., Vicent, M. J., & Salmaso, S. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b00286 · Cited by 65
Kuai, Y., Gong, X., Ding, L., Li, F., Lei, L., Gong, Y., Liu, Q., Tan, H., Zhang, X., Liu, D., et al. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0258-6 · Cited by 64
The Human Cdc37·Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy
Sreeramulu, S., Jonker, H. R. A., Langer, T., Richter, C., Lancaster, C. R. D., & Schwalbe, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806715200 · Cited by 62
Trougakos, I. P., Sesti, F., Tsakiri, E. N., & Gorgoulis, V. G. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.02.024 · Cited by 65
“HSP90 exists as a homodimer and functions in the regulation of cell cycle and signaling by binding client proteins and enabling their interaction with their ligands or with other proteins [214].”
Heat Shock Protein as Molecular Targets for Breast Cancer Therapeutics
Kim, L., & Kim, J. H. (2011) · Journal of Breast Cancer · doi:10.4048/jbc.2011.14.3.167 · Cited by 61
“Thereafter, many studies demonstrated that HSPs are a highly conserved family of proteins either expressed constitutively or regulated inductively by various cellular stresses such as inflammation, toxins, hypoxia, and radiation in all living organisms [5,6].”
BackgroundHe, S., Zhang, C., Shafi, A. A., Sequeira, M., Acquaviva, J., Friedland, J. C., Sang, J., Smith, D. L., Weigel, N. L., Wada, Y., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1698 · Cited by 64
“action is likely no longer required; a property distinct to most other client proteins that are generally more reliant on Hsp90 for their stability and function (10,16).”
BackgroundChan, K. C., Ting, C. M., Chan, P. S., Lo, M. C., Lo, K. W., Curry, J. E., Smyth, T., Lee, A. W. M., Ng, W. T., Tsao, G. S., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-128 · Cited by 64
“Heat shock protein 90 (Hsp90) is a molecular chaperone involved in the maturation and stabilization of over 200 oncogenic client proteins crucial for oncogenesis [6-8].”
BackgroundThe HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Garon, E. B., Finn, R. S., Hamidi, H., Dering, J., Pitts, S. L., Kamranpour, N., Desai, A. J., Hosmer, W., Ide, S. E., Avşar, E., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0998 · Cited by 71
“On the basis of these data, as well as a long list of client proteins important in malignancy (3), HSP90 has emerged a promising therapeutic target (1).”
BackgroundInfluential
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.